Menu

Report Library

All Reports

Q3 2015 Outlook Report

July 09, 2015

In this quarter's report, we cover catalysts from 24 drugs, devices and diagnostics. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q3 2015 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Q2 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 100% of catalyst outcomes that occurred in Q2 2015.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: Alzheimer's Disease (AD)
Atopic Dermatitis (Eczema)
Behçet Syndrome
Breast Cancer
Chemotherapy Induced Nausea and Vomiting (CINV)
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Chronic Idiopathic Constipation
Crohn's Disease
Diabetes Mellitus, Type I
Dyslipidemia / Hypercholesterolemia
Female Sexual Arousal Disorder
Glaucoma / Ocular Hypertension (Ophthalmology)
Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)
Hypophosphatasia
Lysosomal Acid Lipase Deficiency
Major Depressive Disorder (MDD)
Mesothelioma
Neuroendocrine Tumors (NET)
Non-Small Cell Lung Cancer (NSCLC)
Schizophrenia

 Additional Resources: